New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for ...

Add Yahoo as a preferred source to see more of our stories on Google. When we think of movement disorders, the tremors associated with Parkinson’s disease are probably what first spring to mind.

Incubated by Atlas Venture, the biotech startup is advancing a daily pill it sees potentially helping people with dystonia or ...

Jonathan Allen first picked up the trombone in the fourth grade. After playing for years, he eventually earned a doctorate in musical arts and a teaching position at the University of Iowa. Then, one ...

Massachusetts-based biotech Vima Therapeutics has extended its Series A financing by $40m to advance its investigational Parkinson’s and dystonia pill, VIM0423. This takes the company’s total funding ...

Medically reviewed by Nicholas R. Metrus, MD Tardive dyskinesia and dystonia are movement disorders with different causes and onset of symptoms.Treatment for both disorders may involve anticholinergic ...

US biotech Vima Therapeutics has secured $40 million in a series A extension to support development of its oral movement-disorder therapy VIM0423, bringing the total financing round to $100 million.

A recent grant award in the Department of Neurology serves to help investigators analyze how a group of brain cells may be responsible for changes to neural circuits that lead to the movement disorder ...

Oct. 14 (UPI) --A new award will help early career researchers who study dystonia, the Michael J. Fox Foundation announced Tuesday. The new Bachmann-Strauss Early Career Award is a two-year, $150,000 ...

KNOXVILLE, Tenn. (WATE) — September is National Dystonia Awareness Month. Dystonia is a chronic movement disorder affecting the brain and nervous system. If you are like a lot of people, you might not ...

New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson’s diseaseFirst ...